| Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage: a multicenter prospective cohort study TL Nickolas, KM Schmidt-Ott, P Canetta, C Forster, E Singer, M Sise, ... Journal of the American College of Cardiology 59 (3), 246-255, 2012 | 451 | 2012 |
| APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy N Papeta, K Kiryluk, A Patel, R Sterken, N Kacak, HJ Snyder, PH Imus, ... Journal of the American Society of Nephrology 22 (11), 1991-1996, 2011 | 143 | 2011 |
| Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide AE DeZern, ML Zahurak, HJ Symons, KR Cooke, GL Rosner, ... Blood Advances 4 (8), 1770-1779, 2020 | 134 | 2020 |
| CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity M Naeimi Kararoudi, Y Nagai, E Elmas, M de Souza Fernandes Pereira, ... Blood, The Journal of the American Society of Hematology 136 (21), 2416-2427, 2020 | 108 | 2020 |
| Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide AE DeZern, C Franklin, HL Tsai, PH Imus, KR Cooke, R Varadhan, ... Blood advances 5 (5), 1360-1368, 2021 | 74 | 2021 |
| Severe cytokine release syndrome after haploidentical peripheral blood stem cell transplantation PH Imus, AL Blackford, M Bettinotti, L Luznik, EJ Fuchs, CA Huff, ... Biology of Blood and Marrow Transplantation 25 (12), 2431-2437, 2019 | 73 | 2019 |
| Major histocompatibility mismatch and donor choice for second allogeneic bone marrow transplantation PH Imus, AL Blackford, M Bettinotti, B Iglehart, A Dietrich, N Tucker, ... Biology of Blood and Marrow Transplantation 23 (11), 1887-1894, 2017 | 67 | 2017 |
| Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide LK Schoch, KR Cooke, ND Wagner-Johnston, I Gojo, LJ Swinnen, P Imus, ... Blood advances 2 (17), 2226-2229, 2018 | 57 | 2018 |
| Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia AE DeZern, M Zahurak, HJ Symons, KR Cooke, CA Huff, T Jain, ... Blood, The Journal of the American Society of Hematology 141 (25), 3031-3038, 2023 | 41 | 2023 |
| Deep learning for diagnosis of acute promyelocytic leukemia via recognition of genomically imprinted morphologic features JW Sidhom, IJ Siddarthan, BS Lai, A Luo, BC Hambley, J Bynum, ... NPJ precision oncology 5 (1), 38, 2021 | 38 | 2021 |
| Allogeneic transplantation for Ph+ acute lymphoblastic leukemia with posttransplantation cyclophosphamide JA Webster, L Luznik, HL Tsai, PH Imus, AE DeZern, KW Pratz, MJ Levis, ... Blood Advances 4 (20), 5078-5088, 2020 | 32 | 2020 |
| Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide AE DeZern, H Elmariah, M Zahurak, GL Rosner, DE Gladstone, SA Ali, ... Biology of blood and marrow transplantation 26 (11), 2075-2081, 2020 | 25 | 2020 |
| Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70 PH Imus, HL Tsai, L Luznik, EJ Fuchs, CA Huff, DE Gladstone, P Lowery, ... Blood advances 3 (17), 2608-2616, 2019 | 25 | 2019 |
| Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis T Jain, HL Tsai, AE DeZern, LP Gondek, H Elmariah, J Bolaños-Meade, ... Transplantation and cellular therapy 28 (5), 259. e1-259. e11, 2022 | 20 | 2022 |
| Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma RS Greenberg, JA Ruddy, BJ Boyarsky, WA Werbel, JM Garonzik-Wang, ... BMC cancer 21, 1-5, 2021 | 15 | 2021 |
| BCMA CAR T cells: the winding path to success I Borrello, PH Imus The Journal of clinical investigation 129 (6), 2175-2177, 2019 | 14 | 2019 |
| Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group … LJ Swinnen, A O’Neill, PH Imus, S Gujar, D Schiff, LR Kleinberg, ... Oncotarget 9 (1), 766, 2018 | 14 | 2018 |
| The Composite Health Risk Assessment Model (CHARM) to predict 1-year non-relapse mortality (NRM) among older recipients of allogeneic transplantation: A prospective BMT-CTN … A Artz, BR Logan, W Saber, N Geller, A Bellach, J Kou, W Wood, ... Blood 142, 109, 2023 | 12 | 2023 |
| An allogeneic multiple myeloma GM-CSF–secreting vaccine with lenalidomide induces long-term immunity and durable clinical responses in patients in near complete remission L Biavati, CA Huff, A Ferguson, A Sidorski, MA Stevens, L Rudraraju, ... Clinical Cancer Research 27 (24), 6696-6708, 2021 | 12 | 2021 |
| Thrombotic microangiopathy after post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis PH Imus, HL Tsai, AE DeZern, K Jerde, LJ Swinnen, J Bolaños-Meade, ... Biology of Blood and Marrow Transplantation 26 (12), 2306-2310, 2020 | 12 | 2020 |
